Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer
The combination of nivolumab with ipilimumab has been proven to [...]
ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer
Results from the ENTRATA clinical trial to assess telaglenastat in [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
ASCO 2019: Safety and efficacy of immune checkpoint inhibitors in patients with pre-existing autoimmune disorders
This study was presented at the American Society of Clinical [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
Pembrolizumab plus axitinib granted FDA approval for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
Dalantercept plus axitinib combination for advanced kidney cancer
The results from a recent phase II study comparing a [...]
Patients may not be able to tolerate recommended dose of cabozantinib
A recent study published on Oncology this month suggests that [...]
Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer
The results of a recent phase 2 study to evaluate [...]
